SpringWorks reports conditional approval of Ezmekly in EU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 18 2025
0mins
Approval Announcement: SpringWorks Therapeutics received conditional marketing authorization from the European Commission for EZMEKLY, the first therapy approved in the EU for treating symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 aged 2 and above.
Clinical Trial Results: The approval is based on positive results from the Phase 2b ReNeu trial, which showed an objective response rate of 41% in adults and 52% in children among the 114 enrolled patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
